Detailed product reference
Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.
Product overview
Samsca is a vasopressin-V2 antagonist producing aquaresis; Japanese formulation/strength approvals differ.
Read source section ↗Mechanism of action
Blocks collecting-duct V2 signaling, reducing water reabsorption; serum sodium may rise.
Read source section ↗Japanese indications & eligibility
7.5 mg/granules have broader uses; 15 mg excludes cirrhotic fluid retention; 30 mg is for SIADH/selected ADPKD.
Read source section ↗Administration & dose differences
Schedules differ: heart failure often 15 mg daily, cirrhosis 7.5 mg daily; SIADH titrates sodium, ADPKD uses divided titration.
Read source section ↗Adverse effects & key risks
Watch for dehydration, hypernatremia, rapid sodium correction and liver injury.
Read source section ↗Contraindications & special populations
Contraindications include impaired thirst/fluid intake and pregnancy, with additional indication-specific renal/liver/sodium restrictions.
Read source section ↗Drug interactions
Review CYP3A modifiers, grapefruit juice, diuretics and antihypertensives. Follow the clinical fluid plan.
Read source section ↗Assessment & monitoring
Monitor sodium, fluid balance, weight, urine output and indication-specific liver function.
Read source section ↗Storage & handling
Store at room temperature; protect OD tablets from moisture after opening the aluminum pouch.
Read source section ↗Sources & verification
Product checked ·
- PMDA electronic package insert ↗www.pmda.go.jp
Primary source for mechanism, indications, doses and risks; revision: 2025-12.
- Manufacturer information ↗www.otsuka-elibrary.jp
Official product or related information; professional portals may require identity confirmation.
- Wikipedia: ingredient background ↗en.wikipedia.org
Background reference; Japanese approvals and administration are governed by PMDA sources.
